Drugs / BAY 3771249
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07535112 | Apr 2026 → Jul 2029 expected | colorectal adenocarcinoma | Bayer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 3771249 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07535112 ↗ |
| Action | Inhibit | “BAY 3771249, is designed to block the activity of KRAS with G12D mutation” NCT07535112 ↗ |